Here is the design of a clinical trial:

Official Title: A Cluster RCT to Increase HIV Testing in Substance Use Treatment Programs

Included conditions:
- HIV/AIDS
- Hepatitis C
- Substance Use Disorders
- Opioid-use Disorder

Study Armgroups:
- {'label': 'HIV Testing Practice Coaching Intervention Group', 'type': 'EXPERIMENTAL', 'description': 'The HIV Testing Practice Coaching (PC) Intervention is designed to improve the provision and sustained implementation of on-site HIV testing and linkage to care among OTP patients.', 'interventionNames': ['Other: HIV Testing Practice Coaching Intervention']}
- {'label': 'HIV and HCV Testing Practice Coaching Intervention Group', 'type': 'EXPERIMENTAL', 'description': 'The HIV and HCV Testing Practice Coaching (PC) Intervention will leverage the HIV PC intervention and follow the same interventional steps described above, and, in addition, provide information and training to support joint HIV/HCV testing and linkage to care among OTP patients.', 'interventionNames': ['Other: HIV and HCV Testing Practice Coaching Intervention']}
- {'label': 'Information Control Group', 'type': 'OTHER', 'description': 'The administrators of OTPs assigned to the control condition will receive a website link to and hard copy of the NIDA/SAMHSA Blending Initiative product for HIV rapid testing.', 'interventionNames': ['Other: Information Control']}

Interventions:
- {'type': 'OTHER', 'name': 'Information Control', 'description': 'The OTPs assigned to this group will be provided access to the NIDA/SAMHSA Blending Initiative product for HIV rapid testing. Resources generated from the HIV rapid testing Blending Initiative product include a fact sheet, resource guide, marketing materials, and an Excel-based budgeting tool. In addition to the HIV-specific materials, the website provides opportunities for training, self-study progress, workshop, and distance learning. OTPs also will receive a link to the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention training website which provides information and training courses. Sites also will receive a hard (or electronic) copy of the ARTAS implementation manual and information about the provision of HIV testing, linkage to care and PrEP.', 'armGroupLabels': ['Information Control Group']}
- {'type': 'OTHER', 'name': 'HIV and HCV Testing Practice Coaching Intervention', 'description': 'The practice coaches (PCs) will work with the program team a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV and HCV testing and evidence--based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV and HCV testing. Also, due to the expense of HCV treatment, and potentially more complicated mechanisms for linking HCV-positive patients to further evaluation and care which may take more time than anticipated, PCs will provide OTPs with basic education and motivation about the importance of HCV testing for reasons other than immediate curative treatment. Information on PrEP also will be provided. The intervention will occur over approximately 29 weeks (or 6 months).', 'armGroupLabels': ['HIV and HCV Testing Practice Coaching Intervention Group']}
- {'type': 'OTHER', 'name': 'HIV Testing Practice Coaching Intervention', 'description': 'The practice coaches (PCs) will work with the programs a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV testing and evidence-based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV testing. Information on Pre-Exposure Prophylaxis (PrEP) also will be provided. The intervention will occur over approximately 29 weeks (or 6 months) consisting of four distinct evidence-based phases designed to establish competency in the implementation of organizational change towards establishing HIV testing outcomes among OTP clientele.', 'armGroupLabels': ['HIV Testing Practice Coaching Intervention Group']}

Primary Outcomes:
- {'measure': 'Proportion of OTP patients HIV tested at 6 months post intervention or control, while controlling for HIV testing during the baseline period (T1)', 'description': 'The primary outcome measure will be a contrast of the proportion of OTP patients HIV tested during T3, controlling for HIV testing at baseline (T1). The primary test will be whether the proportion of patients tested across the two PC interventions--HIV Testing PC Intervention Group and HIV/HCV Testing PC Intervention Group--differs from the proportion of patients tested in the Information Control Group.', 'timeFrame': 'The period 7-12 months post site-randomization (T3).'}

Please estimate the sample size based on the assumption: 
Intra-class correlations (ICC) range from 0.04 to 0.08. Over 95% power for the primary outcome and 85% power for the secondary outcome. If some sites drop out, over 95% power for the primary and 83% power for the secondary with 45 sites remaining. Over 80% power for the quasi-experimental evaluation and analysis of change in proportion of facilitators/barriers.
Power and sample size
      Statistical power and sample size were determined using a simulation programmed in SAS 9.3. The simulation generated data with a range of intra-class correlations (ICC) from 0.04 to 0.08, and an information control condition with a proportion of clientsâ HIV testing of 20% as found in the control condition in CTN0032, a study assessing the relative effectiveness of three HIV testing strategies on increasing receipt of test results and reducing HIV risk behaviors among patients seen at drug use treatment centers [13]. A sample size of 51 OTPs and an average of about 100 clients per site per 6-month period provides over 95% power for the primary outcome and 85% power for the secondary outcome if the proportion of clientsâ HIV testing in the HIV PC condition is 30% (absolute difference of 10% from control condition) and the proportion of clientsâ HIV testing in the HIV/HCV PC condition is 41% (absolute difference of 11% from the HIV PC condition) for all expected levels of ICC (0.04 to 0.08). Should some sites drop out, there is still over 95% power for the primary and 83% power for the secondary, as long as 45 sites remain in the study. For the quasi-experimental evaluation of the blending product, the study will have over 80% power to uncover an absolute change in proportion testing for HIV of 6 to 7%. For analysis of change in proportion of facilitators/barriers, the study will have over 80% power to uncover a significant difference in change if the difference in change is 0.5 to 0.65 of a standard deviation, a medium effect size.